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How should individual participant data
(IPD) from publicly funded clinical trials be
shared?
C. Tudur Smith1*, C. Hopkins1, M. R. Sydes2, K. Woolfall3, M. Clarke4, G. Murray5 and P. Williamson1
Abstract
Background: Individual participant data (IPD) from completed clinical trials should be responsibly shared to support
efficient clinical research, generate new knowledge and bring benefit to patients. The Medical Research Council (MRC)
Hubs for Trials Methodology Research (HTMR) has developed guidance to facilitate the sharing of IPD from publicly
funded clinical trials.
Methods: Development of the guidance was completed over four phases which included a focussed review of policy
documents, a web-based survey of the UK Clinical Research Collaboration (CRC) Registered Clinical Trials Units (CTU)
Network, participation of an expert committee and an open consultation with the UKCRC Registered CTU Network. The
project was funded by the MRC HTMR (MR/L004933/1-R39).
Results: Good practice principles include: (i) the use of a controlled access approach, using a transparent and
robust system to review requests and provide secure data access; (ii) seeking consent for sharing IPD from trial
participants in all future clinical trials with adequate assurance that patient privacy and confidentiality can be
maintained; and (iii) establishing an approach to resource the sharing of IPD which would include support from
trial funders, sponsor organisations and users of IPD. The guidance has been endorsed by Cancer Research UK,
MRC Methodology Research Programme Advisory Group, Wellcome Trust and the Executive Group of the UKCRC
Registered CTU Network. The National Institute for Health Research (NIHR) has confirmed it is supportive of the
application of this guidance.
Conclusions: Implementation of these principles will improve transparency, increase the coherent sharing of IPD from
publicly funded trials, and help publicly funded trials to adhere to trial funder and journal requirements for data sharing.
Keywords: Data sharing, Individual participant data, IPD, Clinical trial, Publicly funded, CTU, Good practice
Background
Before a clinical trial begins recruiting participants the
trial should be ‘registered’ in a clinical trials registry such
as ClinicalTrials.gov. This public record of completed
and ongoing trials assures transparency and reduces the
potential for publication bias, which is known to be a
significant problem in medical research [1]. During a
clinical trial data are collected about each individual
participant. This may include participant characteristics
(e.g. age, gender), clinical measurements (e.g. blood
pressure, heart rate), medical history (e.g. history of dia-
betes), clinical laboratory results (e.g. white blood cell
count), images (e.g. X-rays), adverse events (e.g. gastro-
intestinal bleeding events), clinical outcome (e.g. death),
and details of randomisation and treatment received. These
data are referred to as individual participant data (IPD).
At the end of a clinical trial, results are generated by
summarising the IPD to evaluate the effect of interven-
tions administered during the clinical trial. The sum-
mary results should be fully reported and published in
medical journals [2] and trial registries, but utility of the
IPD continues as they provide enormous potential to in-
vestigate further clinical and/or methodological questions
beyond those that the trial had been originally designed to
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address. Several clinical trial funders and journals now re-
quire that the IPD from a clinical trial is made available
on reasonable request [3–6] after completion of the trial.
There are numerous examples in the medical literature
that demonstrate the value of IPD and what can be
achieved through data sharing. This includes improving
the reliability and robustness of comparative meta-analyses
in cancer [7], cardiovascular disease [8] and epilepsy [9];
the reliable identification of subgroups of patients that
benefit most from treatment [10]; aiding the development
of new methodology [11]; and providing the best evidence
to inform the development of clinical guidelines [12] and
new clinical trials [13]. Greater access to IPD and clinical
study reports has been incredibly useful to help overcome
the problem of bias in the medical literature with high pro-
file examples focussing on Tamiflu [14] and Paroxetine
[15], in which more reliable and balanced information has
been generated for patients and clinical practitioners.
Despite the advantages and potential usefulness, IPD is
often unavailable [16–18], or may be shared but using
responsive ad hoc approaches which limits discoverability,
productivity and the potential preservation of valuable
data sets. Failure to exploit existing data means that new
data are collected unnecessarily which creates unaccept-
able waste in clinical research [19]. Attitudes are changing,
and the pharmaceutical industry [20, 21], drug regulators
[22] and the clinical trial community [23, 24] are taking
steps to improve things. For the publicly funded trials
sector there are examples of good practice [25] but pro-
gress towards sharing IPD from clinical trials using a co-
hesive and consistent approach is slow. More now needs
to be done to encourage proactive sharing using common
principles of good practice.
In this article we summarise the process used to de-
velop a guidance document for publicly funded clinical
trials and outline the key principles of good practice that
aim to increase and improve the uptake of responsible
data sharing in this key stakeholder group.
Methods
Development of the guidance was funded by the Medical
Research Council (MRC) Network of Hubs for Trials
Methodology Research (HTMR). A project group including
statisticians, clinical trialists, systematic reviewers and
methodologists was established to develop the guidance, a
process that was completed over four phases.
During phase 1 a focussed search for data sharing policy
documents was conducted to identify good practices for
responsible sharing of IPD. We searched ‘Google Search’
and the University of Liverpool Discover database (search
terms provided in Additional file 1). We used NVivo soft-
ware to assist the management and indexing of themes and
sub-themes identified within and across policy documents.
We created theme summary reports to assist the develop-
ment of guidance.
During phase 2 a web-based survey of the UK Clinical
Research Collaboration (CRC) Registered Clinical Trials
Units (CTU) Network was undertaken to ascertain
current data sharing activities, good practices and pos-
sible barriers to sharing IPD from the perspective of or-
ganisations coordinating publicly funded clinical trials.
Full details of the survey methods and results have been
published elsewhere [26]. In brief, a 47-item question-
naire was developed and conducted online using Select-
Survey.NET. Ethical approval was obtained from the
University of Liverpool Research Ethics Committee and
as the survey was conducted online, completion was
regarded as consent to participate. A link to the survey
was emailed to the Directors of 45 CTUs within the
UKCRC Registered CTU Network in April 2014, with
email reminders sent after 2, 4 and 6 weeks. The ques-
tionnaire took approximately 15 minutes to complete.
The project group used the information gathered from
phase 1 and 2 to develop a draft guidance document sum-
marising the principles of good practice. During phase 3
the draft guidance was circulated to a committee of 13 se-
lected experts, with six representatives from UK publicly
funded CTUs that generate clinical trial IPD or UK aca-
demic institutions with expertise in using IPD for research
purposes, three from pharmaceutical companies in the
UK and US, two from UK clinical trial funding bodies,
and two from an independent company with knowledge
in the area of sharing clinical trial IPD (Additional file 2:
Appendix 4). A one-day meeting involving members of
the project group and expert committee was held in
London during November 2014 to discuss the guidance,
and an iterative process used to update and revise the
draft guidance to incorporate comments from the expert
committee. During phase 4 the revised guidance was cir-
culated to the Directors of the 45 UKCRC Registered
CTU Network and a period of open consultation was used
to obtain further comments which were incorporated into
the final version of the guidance. The full guidance is
available as Additional file 2 and from the MRC HTMR
website (http://www.methodologyhubs.mrc.ac.uk/files/711
4/3682/3831/Datasharingguidance2015.pdf). The key prin-
ciples, repeated verbatim from the full guidance, are sum-
marised in this article.
Results
Support for the guidance
The guidance has been endorsed by Cancer Research
UK, MRC Methodology Research Programme Advisory
Group, Wellcome Trust and the Executive Group of
the UKCRC Registered CTU Network. The National In-
stitute for Health Research (NIHR) has confirmed it is
supportive of the application of this guidance.
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Summary of guidance
Results of the survey conducted in phase 2 have been pub-
lished elsewhere [26]. In brief, the CTUs were supportive
of the principle of sharing IPD but common concerns
were raised about the inappropriate reuse of clinical trial
data, the additional resource required for publicly funded
CTUs to prepare and share data, the potential loss of
ability to publish further research, and the potential risk to
trial participant privacy. The use of a controlled access ap-
proach (Fig. 1) such as that used by MRC CTU at
University College London (UCL) [25], the Yale University
Open Data Access Project (YODA) [27] and Clinical
Study Data Request (CSDR) [21] with systems in place to
review data access requests from researchers, was the pre-
ferred approach and this has been assumed throughout.
The ‘data custodian’ is defined within the guidance as a
research group, company, organisation or sponsor that
collects, manages and stores data from a clinical trial, and
would be responsible for data sharing. The data custodian
of publicly funded clinical trials would need to consider a
number of data sharing activities that could arise through-
out the clinical trial process (Fig. 2, Box 1 and Box 2).
Fig. 1 Flow chart of activities in a controlled access model
Fig. 2 Data sharing activities through a clinical trial process
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Box 1 - Good practice at the data custodian (e.g. CTU) level
Policy
 A data sharing policy should be developed by the data custodian organisation outlining the general approach to data sharing,
summarising the elements discussed below. The policy should align with any other overarching policies, e.g. host organisation
policy, funder policies
Scope
 IPD and associated documentation should be made available for all prospective publicly funded clinical trials. Requests for data
from historical clinical trials should be dealt with on a case-by-case basis
 IPD should be made available as soon as reasonably possible, e.g. 18 months after trial completion
Data request process
 Sponsor approval for data sharing should be sought (sponsor might initially agree principles of data sharing but delegate
responsibility for implementing data sharing to the data custodian)
 Only bona fide research groups should be eligible to access data (e.g. evidenced via CVs and the involvement of a
qualified statistician)
 Data access requests should be made via an application form detailing the specific requirements and the proposed research and
publication plan
 Data access requests should be reviewed against specific criteria by data custodians (e.g. trial statistician and Chief Investigator) or
by an external Independent Review Panel. Decisions about requests should be made promptly according to a published schedule
(no more than 3 months after receipt of request)
 Details of all data requests and their outcomes, with clear rationale for any refusals, should be made publicly available. Data requesters
should be informed of this in advance
Data release process
 Data should be made available as soon as possible after approval of requests
 Data should be made available on a secure server or via other secure data transfer method
 Supporting documentation should be supplied with the dataset
Data use agreement
 A data use agreement should be utilised which, at a minimum: (i) prohibits attempts to re-identify or contact trial participants; (ii)
addresses any requirements regarding planned outputs of proposed research, e.g. publication and acknowledgement requirements;
and (iii) prohibits non-approved uses or further distribution of the data
Resources
 Funds for responsible data sharing should be requested by the original trial team from trial funders as part of initial trial grant
applications, e.g. to fund dataset preparation and anonymisation
 Reasonable costs may be recovered from data requesters if appropriate but data sharing activities should not be profit generating
 Host organisations (e.g. Institute of Higher Education) may be able to provide funds for routine data sharing activities, e.g. ongoing
maintenance of a data sharing system
 Responsibilities of staff for data sharing should be determined and funding should be sourced
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Activities can be separated into those that occur at the
level of a data custodian’s organisation and which are ap-
plicable across multiple trials (Box 1), and also those ac-
tivities that occur each time an individual trial is
conducted (Box 2). The ‘sponsor’ of the trial has ultim-
ate responsibility for authorising the release of data but
in many publicly funded clinical trials the ‘sponsor’ may
delegate responsibility for activities of data collection
and storage to the ‘data custodian’ (e.g. the Chief Investi-
gator’s hosting University or NHS Trust may be the
‘sponsor’ but the ‘data custodian’ would be the CTU co-
ordinating the trial), and so a clear process is required to
ensure that sponsor approval for data sharing is pro-
vided. Further details of the principles are provided in
the full guidance (Additional file 2).
Conclusions and discussion
We have developed good practice guidance for organisa-
tions that conduct publicly funded clinical trials. Al-
though the guidance has been developed with UK
publicly funded trials in mind, many of the principles
apply to clinical trials coordinated by the private sector
and to organisations conducting clinical trials in coun-
tries other than the UK. Implementation of these princi-
ples will improve transparency and increase the
coherent sharing of IPD to support clinical research and
benefit patients. More research is needed to help im-
prove the discoverability of these valuable data [30] and
we would recommend that the CONSORT checklist [31]
for reporting of randomised controlled trials (RCTs) be
updated to include a specific item about data sharing
Box 2 - Good practice at the individual trial level
Prior to trial funding
 Identify data sharing stakeholders for a trial early on (e.g. sponsor, funder, Chief Investigator, trial management group, CTU) and
highlight the data sharing policy
 Understand the trial funder’s policy and include plans and reasonable costs (if appropriate) for sharing IPD within the trial grant
application
During trial set-up
 Identify roles and responsibilities for data sharing activities and include on a delegation log
 Include outline plans for data sharing in the protocol (see SPIRIT checklist item 31c [28])
 Include detailed plans for data sharing in the trial data management plan
 Include a data sharing statement in the consent form and information in the patient information leaflet. The Health Research
Authority [29] currently recommend the following wording: “I understand that the information collected about me will be used to
support other research in the future, and may be shared anonymously with other researchers.”
 Annotate the complete set of blank case report forms (CRFs) so that they clearly describe the data variable labels and values contained
within the electronic dataset. This may not be required if dataset specifications and blank CRFs are sufficiently detailed to enable
matching of data variables from CRFs to the electronic dataset (note: blank CRFs made available on the organisation’s website, or some
other forum, would help researchers identify relevant data that have been collected prior to submitting a formal request for data)
End of trial
 Prepare the anonymised dataset ready for sharing. The level of anonymisation should be determined in conjunction with other
considerations, such as original patient consent and method of data transfer
 Dataset preparation should be done by individuals with an understanding of data management and basic statistics, with quality
control provided by a further individual who is independent of the process
 Prepare ‘data pack’ ready for sharing. This would typically include: (i) electronic datasets in a suitable format that is recognised by a
range of statistical software, that could be easily divided to create a subset of data if required for the use case requested; and (ii)
supporting documentation (minimum requirement would be protocol with amendments, blank CRFs, dataset specifications
including data variable amendments). Timing of data pack preparation may be reactive or proactive.
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and where IPD for the trial can be located. As many
medical journals and clinical trial funders now require
authors to make their data available, the wider adoption
of the principles outlined in this guidance will aid com-
pliance with funder and journal policies on data sharing.
A UKCRC data sharing task and finish group has re-
cently been established to help encourage sharing IPD
from clinical trials and support the implementation of
the good practice outlined in this guidance. This is a
critical component of this project and we will report on
our experiences in due course. Researchers who imple-
ment this guidance are strongly encouraged to share
their experience of how the principles work in practice
to inform future updates of the guidance.
Availability of data
The de-identified survey data will be made available
for research purposes by contacting the first author
(cat1@liv.ac.uk).
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